And, patients with CRC and type 2 diabetes have a higher risk of mortality than those without T2DM
TUESDAY, Nov. 29 (HealthDay News) -- For patients with nonmetastatic colorectal cancer (CRC), prediagnosis, but not postdiagnosis, body mass index (BMI) is an important predictor of all-cause and cause-specific mortality; and patients with type 2 diabetes mellitus (T2DM) have a higher risk of mortality, according to two studies published online Nov. 28 in the Journal of Clinical Oncology.
Peter T. Campbell, Ph.D., from the American Cancer Society in Atlanta, and colleagues examined the association of pre- and postdiagnosis BMI with all-cause and cause-specific survival in 2,303 participants in the Cancer Prevention Study-II Nutrition Cohort with nonmetastatic CRC. Compared with normal prediagnosis BMI (18.5 to 24.9 kg/m²), obese BMI (≥30 kg/m²) was significantly associated with a higher risk of mortality from all causes, CRC, and cardiovascular disease (CVD) (relative risk [RR], 1.30, 1.35, and 1.68, respectively). Post-diagnosis BMI showed no correlation with mortality.
Ahmed N. Dehal, M.D., M.P.H.c., from the American Cancer Society in Atlanta, and colleagues investigated the association between T2DM and survival in 2,278 participants in the Cancer Prevention Study-II Nutrition Cohort with nonmetastatic CRC. Patients with CRC and T2DM had a higher risk of all-cause, CRC-specific, and CVD-specific mortality than those without T2DM (RR, 1.53, 1.29, and 2.16, respectively). There was no variation by gender, or by durations of T2DM or insulin use. Insulin use was associated with increased risk of death from all causes and CVD, but not from CRC, compared with no T2DM (RR, 1.68, 3.87, and 0.58, respectively).
"T2DM is associated with poorer prognosis among patients with CRC," Dehal and colleagues write.
Abstract - Campbell
Full Text (subscription or payment may be required)
Abstract - Dehal
Full Text (subscription or payment may be required)
Editorial